未登录

D

David J. Burkhart

ica hn school of medicine at mount sinai

H指数:19

被引数:1,267

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Covalent conjugation of a TLR7/8 agonist to recombinant influenza A virus hemagglutinin provides enhanced immunogenicity and protection against disease from a drifted strain

JOURNAL OF IMMUNOLOGY

IF3.4

2025-11-010

PRE

In silico Discovery and Mechanistic Profiling of STING Agonists Engaging the Transmembrane Domain

基于计算机的STING激动剂发现及其与跨膜域相互作用的机制分析

European Journal of Medicinal Chemistry

IF5.9

2025-09-270

PRE

The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine

TLR7/8激动剂INI-4001增强了Powassan病毒样颗粒疫苗的免疫原性

IF6.5

2025-07-160

OA

Encapsulation of the lipidated TLR7/8 agonist INI-4001 into ionic liposomes impacts H7 influenza antigen-specific immune responses

将脂质化的TLR7/8激动剂INI-4001封装到离子脂质体中会影响H7流感抗原特异性免疫应答

Drug Delivery and Translational Research

IF5.5

2025-07-140

OAAI

Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-07-231

OAAI

Adjuvanted Vaccine Induces Functional Antibodies against Pseudomonas aeruginosa Filamentous Bacteriophages

IF3.4

2024-01-240

OAAI

Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses

IF5.5

2024-01-133

OAAI

Co-Delivery of Novel Synthetic TLR4 and TLR7/8 Ligands Adsorbed to Aluminum Salts Promotes Th1-Mediated Immunity against Poorly Immunogenic SARS-CoV-2 RBD

IF3.4

2023-12-232

OAAI

Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge

BIOCONJUGATE CHEMISTRY

IF3.9

2023-09-278

OAAI

A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice

IF6.5

2023-07-106

OAAI

Deciphering immunological mechanisms underlying the efficacy of nanoparticle-based vaccines and novel adjuvants against Opioid Use Disorder (OUD)

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2023-06-010

OAAI

TLR Agonist INI-4001 Improves Efficacy of Heroin Vaccine Intended for Clinical Treatment of Opioid Use Disorder

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2023-06-010

OAAI

Deciphering immunological mechanisms underlying the efficacy of nanoparticle-based vaccines against opioid use disorder (OUD)

JOURNAL OF IMMUNOLOGY

IF3.4

2023-05-010

OA

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination

SCIENTIFIC REPORTS

IF3.9

2022-10-1814

OAAI

Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine

IF5.5

2022-07-125

OAAI

Adjuvanted multivalent vaccine targeting clinically relevant Pf bacteriophage creates cross-reactive antibodies

JOURNAL OF IMMUNOLOGY

IF3.4

2022-05-010

PRE

Cationic Liposomes containing a TLR4 agonist promote the efficient development of cellular immunity against SARS-CoV-2 Spike protein in a subunit vaccine

JOURNAL OF IMMUNOLOGY

IF3.4

2022-05-011

PRE

A novel, synthetic TLR7/8 agonist demonstrates monotherapy efficacy and synergy with anti-PD-1 in syngeneic mouse tumor models

JOURNAL OF IMMUNOLOGY

IF3.4

2022-05-010

PRE

A tractable covalent linker strategy for the production of immunogenic antigen-TLR7/8L bioconjugates

CHEMICAL COMMUNICATIONS

IF4.2

2021-01-019

OAAI

Co-adsorption of synthetic Mincle agonists and antigen to silica nanoparticles for enhanced vaccine activity: A formulation approach to co-delivery

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2021-01-0112

OAAI